Navigation Links
deCODE Conducting Strategic Review to Sharpen the Focus of its Long-term Business
Date:10/15/2008

REYKJAVIK, Iceland, Oct. 15 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced that the company is carrying out a review of its long-term business strategy. Over the past few years deCODE has utilized its capabilities in medicinal chemistry, structural biology and human genetics to develop product and intellectual property portfolios in both therapeutics and DNA-based diagnostics. The goal of this strategic review is to optimize the value of these assets for its shareholders by sharpening the focus of its business, selling non-core assets, securing strategic partnerships, and utilizing the resources generated to underpin product development and marketing efforts in its core business. The company has engaged the Stanford Group Company to assist in evaluating deCODE's strategic alternatives and in executing swiftly on the results of this review through the identification of buyers and partners for non-core business units, programs and intellectual property. deCODE plans to provide an update on this process in its third quarter financial results conference call to be webcast live on November 6.

deCODE also announced that in order to provide more time for the completion of this review and the execution of alternatives including the sale of assets, it has elected to utilize a 30-day grace period for the scheduled October 15 interest payment on its outstanding 3.5% Senior Convertible Notes due 2011.

"We are in the process of creating a smaller, leaner deCODE that will devote its efforts and resources to one line of business. We have created a unique and growing portfolio of intellectual property, as well as a range of products and programs in both our drug development and diagnostics work, and are engaged in
'/>"/>

SOURCE deCODE genetics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. deCODE Launches deCODE BreastCancer(TM), a Genetic Test to Screen for Risk of the Common Forms of Breast Cancer
2. Open Biosystems Launches Decode RNAi Viral Screening Pools for Low-Cost Genome-Scale RNAi Screens
3. deCODE genetics to Webcast Presentation at Piper Jaffray Annual Healthcare Conference
4. deCODE genetics to Webcast Presentation at Lazard Capital Markets Annual Healthcare Conference
5. Wound Management Technologies, Inc. Announces Strategic Plans for Revenue Growth for Year End and 2009
6. Herley Industries, Inc. Engages Jefferies Quarterdeck to Explore Strategic Alternatives
7. ReachMD, LLC Announces New Strategic Partnership With The American Medical Student Association
8. Marex Group Forms Business Development Department and Promotes Three Strategic Employees
9. Covance and Lilly Enter Into a Strategic R&D Collaboration
10. U.S. Preventive Medicine(R) Forms Strategic Alliance with Physicians Planning Group
11. InfoLogix Launches Strategic Mobility Assessment Service for Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)... , WASHINGTON -- A new report from the Institute...ts, duty hours and workloads to decrease the chanc...e the learning environment for these doctors in tr...ucing residents, work hours from the maximum avera... for Graduate Medical Education (ACGME) in 2003, b...
(Date:12/2/2008)...California Health System Builds Resilient, Cost an... , HOPKINTON, Mass., Dec. 2 EM...information infrastructure solutions, today announ...CHS), a regional system of six hospitals spanning ... servers and implemented business continuity funct...
(Date:12/2/2008)...DENVER, Dec. 2 Barotz Dental is no...ring LANAP(TM) (Laser Assisted New Attachment,Pro...tocol that is patented,and FDA approved for new a... LANAP removes diseased tissue, without remov...issue around teeth, minimizes pain and discomfort ...
(Date:12/2/2008)...FISHERS, Ind., Dec. 2 A number of ...ise in childhood obesity, the health risks in,ove... value of cereals and,other foods kids consume. ...- offers all natural, freeze-dried real fruit prod...s, but also provide most, if not all, of the daily...
Breaking Medicine News(10 mins):Health News:Revised hours and workloads for medical residents needed to prevent 2Health News:Revised hours and workloads for medical residents needed to prevent 3Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 2Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 3Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 4Health News:Barotz Dental Now Offering Laser Gum Therapy 2Health News:Moms Find Fun, Healthy Snacks That Help Fight Childhood Obesity 2Health News:Moms Find Fun, Healthy Snacks That Help Fight Childhood Obesity 3
... nutrition while pregnant may be more likely to be... A team from the University of Amsterdam looked at...uring the Dutch famine of 1944-1945 which followed...ey found that the rate of obesity among the women,...
...er antioxidant effects than orange juice. accordin... food. The study states that, people who are look... increased antioxidant consumption might prefer a ...rning to orange juice," says Joe A. Vinson, profes...
...eart disease than those with a full head of hair, ...he Archives of Internal Medicine, said they found ...ease and hair loss. The type of baldness also see...d to develop heart disease.// Those with frontal b...
...ort immunity in elderly, frail and patients at ris... rate of infection is a common risk, especially fo...at the University of Pittsburgh report on the use ...s the immune system in patients undergoing surgery...
Other Medicine News:
(Date:12/2/2008)...re-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ),...prietary antibodies for the treatment of cancer, i...ed that it has entered into an agreement expanding...th Kingsbridge Capital Limited, a private investme...bridge has committed to provide up to $75 million ...
(Date:12/1/2008)...-- TargeGen has announced that an oral,presentati...-based clinical,trial of TG101348 in myeloprolife... 2008 American Society of Hematology (ASH) Meeting...llows:, Title: A Phase I Study ... JAK2-Selective Inhibitor, in Patients w...
(Date:12/1/2008)...gene is a two-way switch that, if turned off, caus...so that they lose their identity and become more l...nn., Dec. 1 Scientists...covered that a certain differentiated cell type is...the constant expression of a gene called Prox1 t...
(Date:12/1/2008)...r Tuesday, December 9 at 11:00 am ET to Discuss Ph...N FRANCISCO, Calif., Dec. 1 /PRNewswire-FirstCal...S ), a biopharmaceutical company focused on the de...erapeutics, today announced new data from its stud...ill be presented during the 50th American Society ...
Breaking Medicine Technology:Micromet Expands Committed Equity Financing Facility to $75 Million 2Micromet Expands Committed Equity Financing Facility to $75 Million 3Micromet Expands Committed Equity Financing Facility to $75 Million 4Micromet Expands Committed Equity Financing Facility to $75 Million 5Micromet Expands Committed Equity Financing Facility to $75 Million 6Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3NO on Prop 8 Campaign Slams Dishonest Mailer Targeting African American Voters 28477 1NO on Prop 8 Campaign Slams Dishonest Mailer Targeting African American Voters 28477 2Easy Ethnic Election 28475 1Easy Ethnic Election 28475 2FDA Faulted for Stance on Chemical in Plastics 28471 1FDA Faulted for Stance on Chemical in Plastics 28471 23SBio Inc Announces Preliminary Third Quarter 2008 Results 8793 13SBio Inc Announces Preliminary Third Quarter 2008 Results 8793 23SBio Inc Announces Preliminary Third Quarter 2008 Results 8793 33SBio Inc Announces Preliminary Third Quarter 2008 Results 8793 43SBio Inc Announces Preliminary Third Quarter 2008 Results 8793 53SBio Inc Announces Preliminary Third Quarter 2008 Results 8793 6
...d at the American College of,Cardiology,s Scientif...RNewswire-FirstCall/ -- CV,Therapeutics, Inc. anno...m the MERLIN TIMI-36 study of ranolazine shows the... patients on ranolazine.,The study did not meet th...the company,s special protocol assessment,agreemen...
...s Across the Genome From 242,Patients and Identifi...astic Leukemia, Suggesting New Targets for Improve...ire/ -- Investigators at,St. Jude Children,s Resea...d mutations that contribute to the formation of pe...st common cancer in,children. The discovery not on...
Other Medicine Technology:CV Therapeutics Announces Topline MERLIN TIMI-36 Results 2CV Therapeutics Announces Topline MERLIN TIMI-36 Results 3Major Gene Study Uncovers Secrets of Leukemia 2Major Gene Study Uncovers Secrets of Leukemia 3
Set of six replacement burrs for E0824 Storz corneal burr set. Dull finish. Most popular size or model.
5.5 mm disk shape burr. Diamond coated tip. Use with E0824 B handle.
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Medium 23 mm. Overall length: 3.9 inches.
One end with needle point and other end with medium taper. Stainless steel. Round knurled handle with polished finish. Overall length: 5.7 inches.
Medicine Products: